Pfizer has kicked off a late-stage trial assessing efficacy and safety of the investigational gene therapy fidanacogene elaparvovec for the treatment of haemophilia B. More: Pfizer kicks off PhIII programme for haemophilia B gene therapy Source: News
read moreAn independent ethics panel in the UK has concluded that genome editing to influence the characteristics of a future person could be “morally permissible”. More: UK panel says human embryo editing ‘morally permissible’ Source: News
read moreThe National Institute for Health and Care Excellence has published a new guideline that aims to address current variation in the provision of services for adults with cerebral palsy. More: NICE issues cerebral palsy guideline for adults Source: News
read moreEuropean regulators have approved Akcea and Ionis’ Tegsedi for patients with hereditary transthyretin amyloidosis (hATTR), a rare disease causing build up of amyloid in the peripheral nervous system and multiple organs. More: EU approval for Akcea/Ionis’ rare disease therapy Source:
read moreThe all new Sales Awards offers a unique opportunity for sales professionals at all levels of their career to sharpen their skills and showcase their talents industry-wide. More: Enter now and showcase your talents industry-wide Source: News
read moreAmgen is staring down some major competitive threats to some of its biggest sellers, meaning an acquisition could be in order. And some industry watchers have just the target in mind. More: Could Amgen soften the Neulasta biosimilar blow with
read more© 1994 - 2026 B.M. Pharmaceuticals